Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 24, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes and Transactions
The filing details share purchases made by the SmithKline Beecham Employee Benefit Trust ("the Trust") on behalf of plan participants following the reinvestment of the cash dividend paid on October 6, 2005. The transactions occurred at a price of GBP 14.5364 per share:
- SmithKline Beecham Bonus Investment Plan: 653 Ordinary shares purchased.
- GlaxoSmithKline Annual Investment Plan: 7,178 Ordinary shares purchased.
Director Mr. J Heslop is noted as having an interest in the shares held in the Trust, consistent with other non-US employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions.
Key Facts for Investor Verification
- Share purchase price of GBP 14.5364 per share on October 24, 2005.
- Total of 7,831 Ordinary shares purchased by the Trust for employee plans.
- Director J Heslop's indirect interest in the Trust shares.
- Transactions were driven by the reinvestment of the October 6, 2005 cash dividend.